Study of HLD-0915 in Patients With Metastatic Prostate Cancer

ConditionMetastatic Prostate Cancer

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexMale

Age18+

SponsorHalda Therapeutics OpCo, Inc.

About this trial

Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

HLD-0915 Hard Capsule
HLD-0915 Tablet
HLD-0915 Soft Capsule

Treatment groups

190 Participants

are divided into 7 treatment groups

Treatment groups

See each treatment group below.

Locations12

Select a site below to view it on the map.

United Kingdom

United States

Colorado

Connecticut

Florida

Massachusetts

Michigan

New York

North Carolina

South Carolina

Tennessee

Texas

Sponsors and collaborators

Halda Therapeutics OpCo, Inc.

Lead sponsor

Source ClinicalTrials.gov